ArriVent BioPharma Reports First Quarter 2024 Financial Results
08 May 2024 //
GLOBENEWSWIRE
InnoCare Announces of First Dosing of the Combination of ICP-189 & Furmonertinib
28 Mar 2024 //
BUSINESSWIRE
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib
30 Oct 2023 //
GLOBENEWSWIRE
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189
13 Sep 2023 //
BUSINESSWIRE